Polaris Group (TW:6550) released its interim analysis report for the Phase III clinical trial of pleural mesothelioma (a type of lung cancer) in the United States on February 25 (U.S. time).
Nanotein Technologies, Inc., an innovative startup biotechnology company in the San Francisco Bay Area, and Polaris Group, a developer of novel treatments for cancer, announced today they have entered into a strategic partnership to advance Nanotein’s protein-based solutions for superior cellular therapy manufacturing.
Taipei, September 17, 2020 – Polaris Group announced today that the first patient has been dosed in a phase 1B trial of ADI‑PEG 20 in combination with Radiotherapy and Temozolomide for the treatment of Newly Diagnosed Glioblastoma Multiforme (GBM). The Lead Investigator is Dr. Wei from Linkou Chang Gung Memorial Hospital. There will be 26 patients enrolled in this phase 1B trial.
